The role of myeloperoxidase as a diagnostic and prognostic factor in cardiovascular pathology (acute coronary syndrome)

Authors

DOI:

https://doi.org/10.14739/2310-1237.2021.2.235805

Keywords:

myeloperoxidase, acute coronary syndrome, myocardial infarction, restenosis, cardiovascular pathology, prognosis, risk stratification

Abstract

Myeloperoxidase is one of the key enzymes involved in oxidative stress and inflammation. Its elevated levels are determined in a wide range of both acute and chronic forms of cardiovascular diseases. The inflammation results in the release of the enzyme from the white blood cells to form products such as hypochlorous acid, which in turn can have a negative effect on the target proteins. Inconsistent evidence on the predictive role of this biomarker in diseases of the circulatory system generates scientific interest and provokes further research in this direction.

The aim of this review is to analyze the scientific literature data on myeloperoxidase as a possible clinical use for the diagnosis and risk stratification of patients with саrdiovascular diseases.

Materials and methods. Searching and generalization of data from leading specialized sources, which are indexed by scientific databases PubMed, SCOPUS, Web of Science.

Results. The results of the studies indicate that myeloperoxidase is actively involved in the pathophysiology of cardiovascular diseases through participation in oxidative stress and inflammation, excessive production of proatherogenic lipoproteins, changes in nitric oxide activity, endothelial dysfunction, and due to the effect on the instability of atherosclerotic plaques. In patients with cardiovascular diseases, including ischemic heart disease, the concentration of the indicated protein is increased and is often associated with a poor prognosis, including an increased risk of mortality. Myeloperoxidase metabolites are often the factors that contribute to cell damage under conditions of ischemia. The review also considers the relationship of the enzyme with the development of restenosis and the effectiveness of revascularization after percutaneous coronary intervention.

Conclusions. The presented data mainly define myeloperoxidase as a significant marker for predicting long-term follow-up results and the development of serious adverse cardiovascular events, mortality in patients with cardiovascular disease. At the same time, despite the great achievements in disclosing the complex effects of myeloperoxidase, inconsistency in the available results is noteworthy. This controversy necessitates further research to elucidate and reveal the full clinical potential of myeloperoxidase in patients with cardiovascular pathology.

Author Biographies

M. P. Kopytsia, GI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv

MD, PhD, DSc, Professor, Head of the Department of Prevention and Treatment of Emergency Conditions

Yu. V. Rodionova, GI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv

MD, PhD, Researcher of the Department of Prevention and Treatment of Emergency Conditions

N. V. Tytarenko, GI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv

MD, PhD, Researcher of the Department of Prevention and Treatment of Emergency Conditions

I. M. Kutia, GI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv

MD, Junior Researcher of the Department of Prevention and Treatment of Emergency Conditions

Ya. V. Нilоva, GI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv

MD, PhD, Researcher of the Department of Prevention and Treatment of Emergency Conditions

References

  1. Stewart, J., Manmathan, G., & Wilkinson, P. (2017). Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM cardiovascular disease, 6, 2048004016687211. https://doi.org/10.1177/2048004016687211
  2. Odobasic, D., Kitching, A. R., & Holdsworth, S. R. (2016). Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase. Journal of immunology research, 2016, 2349817. https://doi.org/10.1155/2016/2349817
  3. Gellhaar, S., Sunnemark, D., Eriksson, H., Olson, L., & Galter, D. (2017). Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Cell and tissue research, 369(3), 445-454. https://doi.org/10.1007/s00441-017-2626-8
  4. Maki, R. A., Holzer, M., Motamedchaboki, K., Malle, E., Masliah, E., Marsche, G., & Reynolds, W. F. (2019). Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. Free radical biology & medicine, 141, 115-140. https://doi.org/10.1016/j.freeradbiomed.2019.05.033
  5. Thai, T., Zhong, F., Dang, L., Chan, E., Ku, J., Malle, E., Geczy, C. L., Keaney, J. F., Jr, & Thomas, S. R. (2021). Endothelial-transcytosed myeloperoxidase activates endothelial nitric oxide synthase via a phospholipase C-dependent calcium signaling pathway. Free radical biology & medicine, 166, 255-264. https://doi.org/10.1016/j.freeradbiomed.2020.12.448
  6. Abdo, A. I., Rayner, B. S., van Reyk, D. M., & Hawkins, C. L. (2017). Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction. Redox biology, 13, 623-632. https://doi.org/10.1016/j.redox.2017.08.004
  7. Love, D. T., Barrett, T. J., White, M. Y., Cordwell, S. J., Davies, M. J., & Hakins, C. L. (2016). Cellular targets of the myeloperoxidase-derived oxidant hpothiocyanous acid (HOSCN) and its role in the inhibition of glycolysis in macrophages. Free radical biology & medicine, 94, 88-98. https://doi.org/10.1016/j.freeradbiomed.2016.02.016
  8. Aratani Y. (2018). Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Archives of biochemistry and biophysics, 640, 47-52. https://doi.org/10.1016/j.abb.2018.01.004
  9. Ndrepepa G. (2019). Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry, 493, 36-51. https://doi.org/10.1016/j.cca.2019.02.022
  10. Khan, A. A., Alsahli, M. A., & Rahmani, A. H. (2018). Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives. Medical sciences, 6(2), 33. https://doi.org/10.3390/medsci6020033
  11. Strzepa, A., Pritchard, K. A., & Dittel, B. N. (2017). Myeloperoxidase: A new player in autoimmunity. Cellular immunology, 317, 1-8. https://doi.org/10.1016/j.cellimm.2017.05.002
  12. Anatoliotakis, N., Deftereos, S., Bouras, G., Giannopoulos, G., Tsounis, D., Angelidis, C., Kaoukis, A., & Stefanadis, C. (2013). Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Current topics in medicinal chemistry, 13(2), 115-138. https://doi.org/10.2174/1568026611313020004
  13. Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Münzel, T., Simoons, M. L., Hamm, C. W., & CAPTURE Investigators (2003). Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108(12), 1440-1445. https://doi.org/10.1161/01.CIR.0000090690.67322.51
  14. Brennan, M. L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J., Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E., & Hazen, S. L. (2003). Prognostic value of myeloperoxidase in patients with chest pain. The New England journal of medicine, 349(17), 1595-1604. https://doi.org/10.1056/NEJMoa035003
  15. Calmarza, P., Lapresta, C., Martínez, M., Lahoz, R., & Povar, J. (2018). Utility of myeloperoxidase in the differential diagnosis of acute coronary syndrome. Archivos de cardiologia de Mexico, 88(5), 391-396. https://doi.org/10.1016/j.acmx.2017.11.003
  16. Tang, W. H., Tong, W., Troughton, R. W., Martin, M. G., Shrestha, K., Borowski, A., Jasper, S., Hazen, S. L., & Klein, A. L. (2007). Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. Journal of the American College of Cardiology, 49(24), 2364-2370. https://doi.org/10.1016/j.jacc.2007.02.053
  17. Avaliani, T., Talakvadze, T., & Tabagari, S. (2019). Prognostic value of plasma myeloperoxidase level's and echocardiographic determinants in chronic heart failure patients. Georgian medical news, (288), 55-60.
  18. McLaughlin, K., Baczyk, D., Potts, A., Hladunewich, M., Parker, J. D., & Kingdom, J. C. (2017). Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension, 69(1), 180-188. https://doi.org/10.1161/HYPERTENSIONAHA.116.08298
  19. Ganz, P., Amarenco, P., Goldstein, L. B., Sillesen, H., Bao, W., Preston, G. M., Welch, K., & SPARCL Steering Committee (2017). Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke, 48(12), 3223-3231. https://doi.org/10.1161/STROKEAHA.117.017965
  20. Correa, S., Pena-Esparragoza, J. K., Scovner, K. M., Waikar, S. S., & Mc Causland, F. R. (2020). Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study. American journal of kidney diseases, 76(1), 32-41. https://doi.org/10.1053/j.ajkd.2019.09.006
  21. Ramachandra, C., Ja, K., Chua, J., Cong, S., Shim, W., & Hausenloy, D. J. (2020). Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxidants & redox signaling, 32(15), 1135-1149. https://doi.org/10.1089/ars.2019.7971
  22. Govindarajan, S., Raghavan, V. M., & Rao, A. C. (2016). Plasma Myeloperoxidase and Total Sialic Acid as Prognostic Indicators in Acute Coronary Syndrome. Journal of clinical and diagnostic research : JCDR, 10(8), BC09-BC13. https://doi.org/10.7860/JCDR/2016/20715.8347
  23. Liu, C., Xie, G., Huang, W., Yang, Y., Li, P., & Tu, Z. (2012). Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients. Journal of atherosclerosis and thrombosis, 19(5), 435-443. https://doi.org/10.5551/jat.9704
  24. Omran, M. M., Zahran, F. M., Kadry, M., Belal, A., & Emran, T. M. (2018). Role of myeloperoxidase in early diagnosis of acute myocardial infarction in patients admitted with chest pain. Journal of immunoassay & immunochemistry, 39(3), 337-347. https://doi.org/10.1080/15321819.2018.1492423
  25. Sawicki, M., Sypniewska, G., Kozinski, M., Gruszka, M., Krintus, M., Obonska, K., Pilaczynska-Cemel, M., & Kubica, J. (2011). Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. European journal of clinical investigation, 41(6), 667-671. https://doi.org/10.1111/j.1365-2362.2010.02457.x
  26. Searle, J., Shih, J., Muller, R., Vollert, J. O., Müller, C., Danne, O., Datwyler, S., & Möckel, M. (2013). The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department. European heart journal. Acute cardiovascular care, 2(3), 203-210. https://doi.org/10.1177/2048872613484688
  27. Trentini, A., Rosta, V., Spadaro, S., Bellini, T., Rizzo, P., Vieceli Dalla Sega, F., Passaro, A., Zuliani, G., Gentili, V., Campo, G., & Cervellati, C. (2020). Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease. Clinical chemistry and laboratory medicine, 58(10), 1749-1758. https://doi.org/10.1515/cclm-2019-0817
  28. Tietge U. (2018). The impact of myeloperoxidase on HDL function in myocardial infarction. Current opinion in endocrinology, diabetes, and obesity, 25(2), 137-142. https://doi.org/10.1097/MED.0000000000000394
  29. Fong, S. W., Few, L. L., See Too, W. C., Khoo, B. Y., Nik Ibrahim, N. N., Yahaya, S. A., Yusof, Z., Mohd Ali, R., Abdul Rahman, A. R., & Yvonne-Tee, G. B. (2015). Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC research notes, 8, 679. https://doi.org/10.1186/s13104-015-1677-8
  30. Tan, Y., Yang, S., Chen, R., Sheng, Z., Zhou, P., Liu, C., Zhao, H., Song, L., Li, J., Zhou, J., Chen, Y., & Yan, H. (2020). High Plasma Myeloperoxidase Is Associated with Plaque Erosion in Patients with ST-Segment Elevation Myocardial Infarction. Journal of cardiovascular translational research, 13(6), 908-915. https://doi.org/10.1007/s12265-020-10002-x
  31. Khan, D. A., Sharif, M. S., & Khan, F. A. (2011). Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction. The Korean journal of laboratory medicine, 31(3), 172-178. https://doi.org/10.3343/kjlm.2011.31.3.172
  32. Stankovic, S., Asanin, M., Trifunovic, D., Majkic-Singh, N., Ignjatovic, S., Mrdovic, I., Matic, D., Savic, L., Marinkovic, J., Ostojic, M., & Vasiljevic, Z. (2012). Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Clinical biochemistry, 45(7-8), 547-551. https://doi.org/10.1016/j.clinbiochem.2012.02.015
  33. Mehta, M. D., Marwah, S. A., Ghosh, S., Shah, H., Trivedi, A., & Haridas, N. (2016). A Synergistic Role of Myeloperoxidase and High Sensitivity Troponin T in the Early Diagnosis of Acute Coronary Syndrome. Indian journal of clinical biochemistry : IJCB, 31(1), 75-80. https://doi.org/10.1007/s12291-015-0490-4
  34. Sinning, C., Schnabel, R., Peacock, W. F., & Blankenberg, S. (2008). Up-and-coming markers: myeloperoxidase, a novel biomarker test for heart failure and acute coronary syndrome application?. Congestive heart failure (Greenwich, Conn.), 14(4 Suppl 1), 46-48. https://doi.org/10.1111/j.1751-7133.2008.tb00012.x
  35. Peacock, W. F., Nagurney, J., Birkhahn, R., Singer, A., Shapiro, N., Hollander, J., Glynn, T., Nowak, R., Safdar, B., Miller, C., Peberdy, M., Counselman, F., Chandra, A., Kosowsky, J., Neuenschwander, J., Schrock, J., Plantholt, S., Lewandrowski, E., Wong, V., Kupfer, K., … Diercks, D. (2011). Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum. American heart journal, 162(5), 893-899. https://doi.org/10.1016/j.ahj.2011.08.017
  36. Stamboul, K., Zeller, M., Rochette, L., Cottin, Y., Cochet, A., Leclercq, T., Porot, G., Guenancia, C., Fichot, M., Maillot, N., Vergely, C., & Lorgis, L. (2017). Relation between high levels of myeloperoxidase in the culprit artery and microvascular obstruction, infarct size and reverse remodeling in ST-elevation myocardial infarction. PloS one, 12(7), e0179929. https://doi.org/10.1371/journal.pone.0179929
  37. Baldus, S., Heitzer, T., Eiserich, J. P., Lau, D., Mollnau, H., Ortak, M., Petri, S., Goldmann, B., Duchstein, H. J., Berger, J., Helmchen, U., Freeman, B. A., Meinertz, T., & Münzel, T. (2004). Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free radical biology & medicine, 37(6), 902-911. https://doi.org/10.1016/j.freeradbiomed.2004.06.003
  38. Ndrepepa, G., Braun, S., Mehilli, J., von Beckerath, N., Schömig, A., & Kastrati, A. (2008). Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. European journal of clinical investigation, 38(2), 90-96. https://doi.org/10.1111/j.1365-2362.2007.01908.x
  39. Goldmann, B. U., Rudolph, V., Rudolph, T. K., Holle, A. K., Hillebrandt, M., Meinertz, T., & Baldus, S. (2009). Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free radical biology & medicine, 47(1), 79-83. https://doi.org/10.1016/j.freeradbiomed.2009.04.004
  40. Rebeiz, A. G., Tamim, H. M., Sleiman, R. M., Abchee, A. G., Ibrahim, Z., Khoury, M. Y., Youhanna, S., Skouri, H. N., & Alam, S. E. (2011). Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. Coronary artery disease, 22(8), 553-558. https://doi.org/10.1097/MCA.0b013e32834c5e98
  41. Kutter, D., Devaquet, P., Vanderstocken, G., Paulus, J. M., Marchal, V., & Gothot, A. (2000). Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta haematologica, 104(1), 10-15. https://doi.org/10.1159/000041062
  42. Jordan, J. E., Zhao, Z. Q., & Vinten-Johansen, J. (1999). The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovascular research, 43(4), 860-878. https://doi.org/10.1016/s0008-6363(99)00187-x
  43. Vinten-Johansen J. (2004). Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular research, 61(3), 481-497. https://doi.org/10.1016/j.cardiores.2003.10.011
  44. Khalil, W., Abdelhamed, M. & Eldamanhory, A. (2021). Validity of QRS Configuration and Myeloperoxidase Level as Determinants of CAD Severity and Prognosis in Patients with STEMI. World Journal of Cardiovascular Diseases, 11, 82-97. https://doi:10.4236/wjcd.2021.111010
  45. Meuwese, M. C., Stroes, E. S., Hazen, S. L., van Miert, J. N., Kuivenhoven, J. A., Schaub, R. G., Wareham, N. J., Luben, R., Kastelein, J. J., Khaw, K. T., & Boekholdt, S. M. (2007). Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. Journal of the American College of Cardiology, 50(2), 159-165. https://doi.org/10.1016/j.jacc.2007.03.033
  46. Khine, H. W., Teiber, J. F., Haley, R. W., Khera, A., Ayers, C. R., & Rohatgi, A. (2017). Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. Atherosclerosis, 263, 156-162. https://doi.org/10.1016/j.atherosclerosis.2017.06.007
  47. Koch, C., Henrich, M., & Heidt, M. C. (2014). Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia. Clinical cardiology, 37(12), 744-749. https://doi.org/10.1002/clc.22336
  48. O'Donoghue, M. L., Morrow, D. A., Cannon, C. P., Jarolim, P., Desai, N. R., Sherwood, M. W., Murphy, S. A., Gerszten, R. E., & Sabatine, M. S. (2016). Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 5(5), e002586. https://doi.org/10.1161/JAHA.115.002586
  49. Oemrawsingh, R. M., Lenderink, T., Akkerhuis, K. M., Heeschen, C., Baldus, S., Fichtlscherer, S., Hamm, C. W., Simoons, M. L., Boersma, E., & CAPTURE investigators (2011). Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart (British Cardiac Society), 97(13), 1061-1066. https://doi.org/10.1136/hrt.2010.197392
  50. Kacprzak, M., & Zielinska, M. (2016). Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. International journal of cardiology, 223, 452-457. https://doi.org/10.1016/j.ijcard.2016.07.258
  51. Kaya, M. G., Yalcin, R., Okyay, K., Poyraz, F., Bayraktar, N., Pasaoglu, H., Boyaci, B., & Cengel, A. (2012). Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Texas Heart Institute journal, 39(4), 500-506.
  52. Zelzer, S., Enko, D., Pilz, S., Tomaschitz, A., März, W., & Meinitzer, A. (2017). Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical biochemistry, 50(13-14), 739-745. https://doi.org/10.1016/j.clinbiochem.2017.03.013
  53. Liu, S. C., Yi, T. C., Weng, H. Y., Zhang, L., Li, Y. X., Mohetaboer, M., Zhang, Y., Jiang, J., Li, J. P., & Huo, Y. (2018). Prognostic value of myeloperoxidase concentration in patients with acute coronary syndrome. Chinese Journal of Cardiology, 46(4), 284-291. https://doi.org/10.3760/cma.j.issn.0253-3758.2018.04.007
  54. Kimak, E., Zięba, B., Duma, D., & Solski, J. (2018). Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. Lipids in health and disease, 17(1), 71. https://doi.org/10.1186/s12944-018-0718-4
  55. Pek, J. H., Fook-Chong, S. M. C., Choo, J. C. J., Tan, C. H. C., Lin, Z., Chan, C. M., Yeo, C. P., & Lim S. H. (2019). Copeptin, myeloperoxidase and pro-adrenomedullin for acute coronary syndrome in patients with chronic kidney disease. Proceedings of Singapore Healthcare, 28(3), 173-183. https://doi.org/10.1177/2010105819843927
  56. Cavusoglu, E., Ruwende, C., Eng, C., Chopra, V., Yanamadala, S., Clark, L. T., Pinsky, D. J., & Marmur, J. D. (2007). Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. The American journal of cardiology, 99(10), 1364-1368. https://doi.org/10.1016/j.amjcard.2006.12.060
  57. Morrow, D. A., Sabatine, M. S., Brennan, M. L., de Lemos, J. A., Murphy, S. A., Ruff, C. T., Rifai, N., Cannon, C. P., & Hazen, S. L. (2008). Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European heart journal, 29(9), 1096-1102. https://doi.org/10.1093/eurheartj/ehn071
  58. Kalantar-Zadeh, K., Brennan, M. L., & Hazen, S. L. (2006). Serum myeloperoxidase and mortality in maintenance hemodialysis patients. American journal of kidney diseases, 48(1), 59-68. https://doi.org/10.1053/j.ajkd.2006.03.047
  59. Roman, R. M., Camargo, P. V., Borges, F. K., Rossini, A. P., & Polanczyk, C. A. (2010). Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coronary artery disease, 21(3), 129-136. https://doi.org/10.1097/MCA.0b013e328333f50d
  60. Wong, N. D., Gransar, H., Narula, J., Shaw, L., Moon, J. H., Miranda-Peats, R., Rozanski, A., Hayes, S. W., Thomson, L. E., Friedman, J. D., & Berman, D. S. (2009). Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC. Cardiovascular imaging, 2(9), 1093-1099. https://doi.org/10.1016/j.jcmg.2009.05.012
  61. Mocatta, T. J., Pilbrow, A. P., Cameron, V. A., Senthilmohan, R., Frampton, C. M., Richards, A. M., & Winterbourn, C. C. (2007). Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. Journal of the American College of Cardiology, 49(20), 1993-2000. https://doi.org/10.1016/j.jacc.2007.02.040
  62. Tang, W. H., Wu, Y., Nicholls, S. J., & Hazen, S. L. (2011). Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clinical chemistry, 57(1), 33-39. https://doi.org/10.1373/clinchem.2010.152827
  63. Tang, W. H., Iqbal, N., Wu, Y., & Hazen, S. L. (2013). Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status. The American journal of cardiology, 111(4), 465-470. https://doi.org/10.1016/j.amjcard.2012.10.027
  64. Nicholls, S. J., Tang, W. H., Brennan, D., Brennan, M. L., Mann, S., Nissen, S. E., & Hazen, S. L. (2011). Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clinical chemistry, 57(12), 1762-1770. https://doi.org/10.1373/clinchem.2011.166827
  65. Scharnagl, H., Kleber, M. E., Genser, B., Kickmaier, S., Renner, W., Weihrauch, G., Grammer, T., Rossmann, C., Winkelmann, B. R., Boehm, B. O., Sattler, W., März, W., & Malle, E. (2014). Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study. International journal of cardiology, 174(1), 96-105. https://doi.org/10.1016/j.ijcard.2014.03.168
  66. Kolodziej, A. R., Abo-Aly, M., Elsawalhy, E., Campbell, C., Ziada, K. M., & Abdel-Latif, A. (2019). Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis. Mediators of inflammation, 2019, 2872607. https://doi.org/10.1155/2019/2872607
  67. Cheng, M., Cheng, M., & Wei, Q. (2020). Association of myeloperoxidase, homocysteine and high-sensitivity C-reactive protein with the severity of coronary artery disease and their diagnostic and prognostic value. Experimental and therapeutic medicine, 20(2), 1532-1540. https://doi.org/10.3892/etm.2020.8817
  68. Teng, N., Maghzal, G. J., Talib, J., Rashid, I., Lau, A. K., & Stocker, R. (2017). The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox report, 22(2), 51-73. https://doi.org/10.1080/13510002.2016.1256119
  69. Apple, F. S., Pearce, L. A., Chung, A., Ler, R., & Murakami, M. M. (2007). Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clinical chemistry, 53(5), 874-881. https://doi.org/10.1373/clinchem.2006.080192
  70. Stefanescu, A., Braun, S., Ndrepepa, G., Koppara, T., Pavaci, H., Mehilli, J., Schömig, A., & Kastrati, A. (2008). Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. American heart journal, 155(2), 356-360. https://doi.org/10.1016/j.ahj.2007.10.017
  71. Eggers, K. M., Dellborg, M., Johnston, N., Oldgren, J., Swahn, E., Venge, P., & Lindahl, B. (2010). Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clinical biochemistry, 43(3), 240-245. https://doi.org/10.1016/j.clinbiochem.2009.09.026
  72. Scirica, B. M., Sabatine, M. S., Jarolim, P., Murphy, S. A., de Lemos, J. L., Braunwald, E., & Morrow, D. A. (2011). Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. European heart journal, 32(6), 697-705. https://doi.org/10.1093/eurheartj/ehq468
  73. Rudolph, V., Keller, T., Schulz, A., Ojeda, F., Rudolph, T. K., Tzikas, S., Bickel, C., Meinertz, T., Münzel, T., Blankenberg, S., & Baldus, S. (2012). Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circulation. Cardiovascular genetics, 5(5), 561-568. https://doi.org/10.1161/CIRCGENETICS.111.962290
  74. Quidim, A. V., Bruno, T. C., Lacerda Leocádio, P. C., Dos Reis Menta, P. L., Alvarez-Leite, J. I., Santos, I. S., Lotufo, P. A., Benseñor, I. M., & Goulart, A. C. (2018). Myeloperoxidase activity and acute coronary syndrome survival: long-term evaluation in the ERICO study. Biomarkers in medicine, 12(11), 1219-1229. https://doi.org/10.2217/bmm-2018-0110
  75. Wang, J., Tan, G. J., Han, L. N., Bai, Y. Y., He, M., & Liu, H. B. (2017). Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology : JGC, 14(2), 135-150. https://doi.org/10.11909/j.issn.1671-5411.2017.02.008
  76. Jiang, H., Zhang, H., Yang, Y., & Yang, X. (2020). Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China. BMJ open, 10(11), e039405. https://doi.org/10.1136/bmjopen-2020-039405
  77. Kukreja, N., Onuma, Y., Garcia-Garcia, H. M., Daemen, J., van Domburg, R., Serruys, P. W., & Interventional Cardiologists of the Thoraxcenter (2000 to 2005) (2009). The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC. Cardiovascular interventions, 2(6), 534-541. https://doi.org/10.1016/j.jcin.2009.04.003
  78. Ikata, J., Wakatsuki, T., Oishi, Y., Oki, T., & Ito, S. (2000). Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coronary atherosclerosis. Coronary artery disease, 11(6), 445-449. https://doi.org/10.1097/00019501-200009000-00001
  79. Miyauchi, K., Kasai, T., Yokayama, T., Aihara, K., Kurata, T., Kajimoto, K., Okazaki, S., Ishiyama, H., & Daida, H. (2008). Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circulation journal, 72(5), 832-838. https://doi.org/10.1253/circj.72.832
  80. Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31(1), 224-230. https://doi.org/10.1016/s0735-1097(97)00450-6
  81. Torrado, J., Buckley, L., Durán, A., Trujillo, P., Toldo, S., Valle Raleigh, J., Abbate, A., Biondi-Zoccai, G., & Guzmán, L. A. (2018). Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. Journal of the American College of Cardiology, 71(15), 1676-1695. https://doi.org/10.1016/j.jacc.2018.02.023
  82. Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010). Inflammation in atherosclerosis: transition from theory to practice. Circulation journal, 74(2), 213-220. https://doi.org/10.1253/circj.cj-09-0706
  83. Tiyerili, V., Camara, B., Becher, M. U., Schrickel, J. W., Lütjohann, D., Mollenhauer, M., Baldus, S., Nickenig, G., & Andrié, R. P. (2016). Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. International journal of cardiology, 204, 29-36. https://doi.org/10.1016/j.ijcard.2015.11.128
  84. Oyenuga, A. O., Couper, D., Matsushita, K., Boerwinkle, E., & Folsom, A. R. (2018). Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study. PloS one, 13(10), e0205310. https://doi.org/10.1371/journal.pone.0205310
  85. Ismael, F. O., Barrett, T. J., Sheipouri, D., Brown, B. E., Davies, M. J., & Hawkins, C. L. (2016). Role of Myeloperoxidase Oxidants in the Modulation of Cellular Lysosomal Enzyme Function: A Contributing Factor to Macrophage Dysfunction in Atherosclerosis?. PloS one, 11(12), e0168844. https://doi.org/10.1371/journal.pone.0168844
  86. Pleva, L., Kusnierova, P., Plevova, P., Zapletalova, J., Karpisek, M., Faldynova, L., Kovarova, P., & Kukla, P. (2015). Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 159(4), 586-594. https://doi.org/10.5507/bp.2015.037
  87. Claessen, B. E., Stone, G. W., Mehran, R., Witzenbichler, B., Brodie, B. R., Wöhrle, J., Witkowski, A., Guagliumi, G., Zmudka, K., Henriques, J. P., Tijssen, J. G., Sanidas, E. A., Chantziara, V., Hakim, D., Leon, S., Xu, K., & Dangas, G. D. (2012). Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of thrombosis and thrombolysis, 34(2), 165-179. https://doi.org/10.1007/s11239-012-0706-x
  88. Ramirez, G. A., Yacoub, M. R., Ripa, M., Mannina, D., Cariddi, A., Saporiti, N., Ciceri, F., Castagna, A., Colombo, G., & Dagna, L. (2018). Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed research international, 2018, 9095275. https://doi.org/10.1155/2018/9095275

Downloads

Published

2021-08-20

How to Cite

1.
Kopytsia MP, Rodionova YV, Tytarenko NV, Kutia IM, Нilоva YV. The role of myeloperoxidase as a diagnostic and prognostic factor in cardiovascular pathology (acute coronary syndrome). Pathologia [Internet]. 2021Aug.20 [cited 2026May25];18(2):229-42. Available from: https://pat.zsmu.edu.ua/article/view/235805

Issue

Vol. 18 No. 2 (2021)

Section

Review

License

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons